Tennessee Valley Asset Management Partners Cellectis S.A. Transaction History

Tennessee Valley Asset Management Partners

$610 Million
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Jan 29, 2024	BUY	$0.97 - $3.55 $2,357 - $8,626	2,430 New	2,430 $7,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

10.8M

Call Options Held

5.9K

Put Options Held

1.4K

Long Focus Capital Management, LLC San Juan, PR

4.62M
Shares

$7.2 Million
0.36% of portfolio
Capital International Investors Los Angeles, CA

1.85M
Shares

$2.88 Million
0.0% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$2.24 Million
0.0% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

1.44M
Shares

$2.24 Million
0.0% of portfolio
Baillie Gifford & CO

694K
Shares

$1.08 Million
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tennessee Valley Asset Management Partners, based on Form 13F filings with the SEC.

News

Stay updated on Tennessee Valley Asset Management Partners with notifications on news.

Account